(VIANEWS) – OneSpaWorld Holdings Limited (OSW), Halozyme Therapeutics (HALO), Citizens Financial Group (CFG) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. OneSpaWorld Holdings Limited (OSW)
34.8% sales growth and 16.12% return on equity
OneSpaWorld Holdings Limited operates health and wellness centers onboard cruise ships and at destination resorts worldwide. Its health and wellness centers offer services, such as traditional body, salon, and skin care services and products; self-service fitness facilities, specialized fitness classes, and personal fitness training; pain management, detoxifying programs, and body composition analyses; weight management programs and products; and medi-spa services. The company also provides its guests access to beauty and wellness brands, including ELEMIS, Kérastase, and Dysport, with various brands offered exclusively in the cruise market. As of March 3, 2021, it offered health, wellness, fitness, and beauty services, treatments, and products onboard 159 cruise ships and at 53 destination resorts. The company is based in Nassau, Bahamas.
Earnings Per Share
As for profitability, OneSpaWorld Holdings Limited has a trailing twelve months EPS of $0.5.
PE Ratio
OneSpaWorld Holdings Limited has a trailing twelve months price to earnings ratio of 24. Meaning, the purchaser of the share is investing $24 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.12%.
Volume
Today’s last reported volume for OneSpaWorld Holdings Limited is 468776 which is 18.13% below its average volume of 572623.
2. Halozyme Therapeutics (HALO)
30.7% sales growth and 110.23% return on equity
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $1.42.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 23.87. Meaning, the purchaser of the share is investing $23.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 110.23%.
Yearly Top and Bottom Value
Halozyme Therapeutics’s stock is valued at $33.90 at 01:22 EST, way below its 52-week high of $59.46 and above its 52-week low of $32.83.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 6.4% and 13.2%, respectively.
3. Citizens Financial Group (CFG)
8.6% sales growth and 8.8% return on equity
Citizens Financial Group, Inc. operates as the bank holding company for Citizens Bank, National Association that provides retail and commercial banking products and services to individuals, small businesses, middle-market companies, corporations, and institutions in the United States. The company operates in two segments, Consumer Banking and Commercial Banking. The Consumer Banking segment offers deposit products, mortgage and home equity lending products, credit cards, business loans, wealth management, and investment services; and auto, education, and point-of-sale finance loans, as well as digital deposit products. This segment serves its customers through telephone service centers, as well as through its online and mobile platforms. The Commercial Banking segment provides various financial products and solutions, including lending and leasing, deposit and treasury management services, foreign exchange, and interest rate and commodity risk management solutions, as well as syndicated loans, corporate finance, mergers and acquisitions, and debt and equity capital markets services. This segment serves government banking, not-for-profit, healthcare, technology, professionals, oil and gas, asset finance, franchise finance, asset-based lending, commercial real estate, private equity, and sponsor finance industries. The company was formerly known as RBS Citizens Financial Group, Inc. and changed its name to Citizens Financial Group, Inc. in April 2014. Citizens Financial Group, Inc. was founded in 1828 and is headquartered in Providence, Rhode Island.
Earnings Per Share
As for profitability, Citizens Financial Group has a trailing twelve months EPS of $3.9.
PE Ratio
Citizens Financial Group has a trailing twelve months price to earnings ratio of 6.71. Meaning, the purchaser of the share is investing $6.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.8%.
Previous days news about Citizens Financial Group(CFG)
- According to MarketWatch on Wednesday, 3 May, "Metropolitan Bank Holding Corp. MCB is down 2.4%, Citizens Financial Group Inc. CFG is up 0.2% after dropping 9% and Western Alliance Bancorp. "
- According to FXStreet on Monday, 1 May, "The FDIC did not specify JPMorgan’s winning bid price, but on Sunday it was reported by several outlets that both PNC FinancialServices (PNC) and Citizens Financial Group (CFG) were also in the running. "
- According to FXStreet on Monday, 1 May, "Over the weekend, roughly a dozen banks, including PNC Financial Services Group, JPMorgan Chase & Co and Citizens Financial Group Inc, have reportedly submitted bids for first Republic Bank as US regulators are trying to finalize the sale. "
- According to FXStreet on Monday, 1 May, "Over the weekend, roughly a dozen banks, including PNC Financial Services Group, JPMorgan Chase & Co and Citizens Financial Group Inc, have reportedly submitted bids for first Republic Bank as US regulators are trying to finalize the sale. "
4. Paychex (PAYX)
7.8% sales growth and 44.96% return on equity
Paychex, Inc. provides integrated human capital management solutions for human resources (HR), payroll, benefits, and insurance services for small to medium-sized businesses in the United States, Europe, and India. It offers payroll processing services; payroll tax administration services; employee payment services; and regulatory compliance services, such as new-hire reporting and garnishment processing. The company also provides HR solutions, including payroll, employer compliance, HR and employee benefits administration, risk management outsourcing, and the on-site availability of a professionally trained HR representative; and retirement services administration, including plan implementation, ongoing compliance with government regulations, employee and employer reporting, participant and employer online access, electronic funds transfer, and other administrative services. In addition, it offers cloud-based HR administration software products for employee benefits management and administration, time and attendance, digital communication solutions, recruiting, and onboarding solutions; plan administration outsourcing and state unemployment insurance services; various business services to small to medium-sized businesses comprising payroll funding and outsourcing services, which include payroll processing, invoicing, and tax preparation; and payment processing services, financial fitness programs, and a small-business loan resource center. Further, the company provides insurance services for property and casualty coverage, such as workers' compensation, business-owner policies, cyber security protection, and commercial auto, as well as health and benefits coverage, including health, dental, vision, and life. It markets and sells its services primarily through its direct sales force. The company was founded in 1971 and is headquartered in Rochester, New York.
Earnings Per Share
As for profitability, Paychex has a trailing twelve months EPS of $4.06.
PE Ratio
Paychex has a trailing twelve months price to earnings ratio of 26.72. Meaning, the purchaser of the share is investing $26.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 44.96%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Paychex’s EBITDA is 7.88.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Feb 7, 2023, the estimated forward annual dividend rate is 3.16 and the estimated forward annual dividend yield is 3%.
Moving Average
Paychex’s value is below its 50-day moving average of $110.12 and below its 200-day moving average of $117.52.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.2%, now sitting on 4.92B for the twelve trailing months.
